leadf
logo-loader
viewBiocept Inc

Biocept reveals $6.6M in top-line growth for 3Q driven by coronavirus RT-PCR testing

Biocept Inc (NASDAQ:BIOC) (FRA:B003) CEO Mike Nall, CFO Tim Kennedy, and Chief Medical Officer Dr Michael Dugan joined Proactive to discuss the group's third-quarter results that saw its revenue jump four-fold year-over-year, driven by the molecular diagnostics company’s astute decision to offer coronavirus (COVID-19) RT-PCR testing.

The trio say offering COVID-19 testing services was the right thing to do, and fully expect this testing to be an important part of the business until the pandemic subsides. Nall adds oncology is still a long-term focus as it continues to build its business for a post-pandemic future.

Quick facts: Biocept Inc

Price: 6.23 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $83.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept reports its liquid biopsy highly accurate in detecting HER2 protein...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the molecular diagnostic assay focused group reported results from a study showing that its Target Selector liquid biopsy was highly accurate in monitoring the HER2 protein alteration in patients with metastatic breast cancer. Nall says...

4 weeks, 1 day ago

2 min read